X0609 4 2026-10-21 0 0001583648 PALVELLA THERAPEUTICS, INC. PVLA 0001912570 Goin Kathleen false C/O PALVELLA THERAPEUTICS, INC. 353 W. LANCASTER AVENUE, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Operating Officer 1 Common Stock 2026-10-21 4 M 0 2165 7.14 A 2165 D Common Stock 2026-10-21 4 M 0 2148 9.08 A 4313 D Common Stock 2026-10-21 4 S 0 2043 123.6214 D 2270 D Common Stock 2026-10-21 4 S 0 1663 125.1645 D 607 D Common Stock 2026-10-21 4 S 0 607 126.1949 D 0 D Stock Option (Right to Buy) 7.14 2026-10-21 4 M 0 2165 0 D 2029-10-29 Common Stock 2165 0 D Stock Option (Right to Buy) 9.08 2026-10-21 4 M 0 2148 0 D 2030-10-14 Common Stock 2148 0 D The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.50 to $124.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.92 to $125.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.92 to $126.518, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The stock option is fully vested. /s/ Kathleen A. McGowan, Attorney-in-Fact 2026-10-23